Triple-negative breast cancer (TNBC) has few therapeutic options, and alternative approaches are urgently needed. Stimulator of IFN genes (
STING) is becoming an exciting target for therapeutic adjuvants. However,
STING resides inside the cell, and the intracellular delivery of CDNs, such as
cGAMP, is required for the optimal activation of
STING. We show that liposomal nanoparticle-delivered
cGAMP (
cGAMP-NP) activates
STING more effectively than soluble
cGAMP. These particles induce innate and adaptive host immune responses to preexisting
tumors in both orthotopic and genetically engineered models of basal-like TNBC.
cGAMP-NPs also reduce
melanoma tumor load, with limited responsivity to anti-PD-L1. Within the tumor microenvironment,
cGAMP-NPs direct both mouse and human macrophages (M), reprograming from protumorigenic M2-like phenotype toward M1-like phenotype; enhance MHC and costimulatory molecule expression; reduce M2
biomarkers; increase IFN-γ-producing T cells; augment
tumor apoptosis; and increase CD4+ and CD8+ T cell infiltration. Activated T cells are required for
tumor suppression, as their depletion reduces antitumor activity. Importantly,
cGAMP-NPs prevent the formation of secondary
tumors, and a single dose is sufficient to inhibit TNBC. These data suggest that a minimal system comprised of
cGAMP-NP alone is sufficient to modulate the tumor microenvironment to effectively control PD-L1-insensitive TNBC.